155 related articles for article (PubMed ID: 2470592)
61. Neuropeptide K: a major tachykinin in plasma and tumor tissues from carcinoid patients.
Theodorsson-Norheim E; Norheim I; Oberg K; Brodin E; Lundberg JM; Tatemoto K; Lindgren PG
Biochem Biophys Res Commun; 1985 Aug; 131(1):77-83. PubMed ID: 2412557
[TBL] [Abstract][Full Text] [Related]
62. [Treatment of carcinoid syndrome with a somatostatin analogue].
Döbrönte Z; Stöckert A; Végh G; Varga L
Orv Hetil; 1992 Mar; 133(12):731-4. PubMed ID: 1372969
[TBL] [Abstract][Full Text] [Related]
63. SMS 201-995-induced stimulation of gastric acid secretion via the dorsal vagal complex and inhibition via the hypothalamus in anaesthetized rats.
Yoneda M; Taché Y
Br J Pharmacol; 1995 Oct; 116(4):2303-9. PubMed ID: 8564264
[TBL] [Abstract][Full Text] [Related]
64. Tachykinin receptors in rabbit airways--characterization by functional, autoradiographic and binding studies.
Black JL; Diment LM; Alouan LA; Johnson PR; Armour CL; Badgery-Parker T; Burcher E
Br J Pharmacol; 1992 Oct; 107(2):429-36. PubMed ID: 1384914
[TBL] [Abstract][Full Text] [Related]
65. Effects of tachykinins on luteinizing hormone release in female rats: potent inhibitory action of neuropeptide K.
Sahu A; Kalra SP
Endocrinology; 1992 Mar; 130(3):1571-7. PubMed ID: 1371455
[TBL] [Abstract][Full Text] [Related]
66. Regional distribution of neuropeptide K and other tachykinins (neurokinin A, neurokinin B and substance P) in rat central nervous system.
Arai H; Emson PC
Brain Res; 1986 Dec; 399(2):240-9. PubMed ID: 2435360
[TBL] [Abstract][Full Text] [Related]
67. Octreotide as a rapid and effective painkiller for metastatic carcinoid tumor.
Katai M; Sakurai A; Inaba H; Ikeo Y; Yamauchi K; Hashizume K
Endocr J; 2005 Apr; 52(2):277-80. PubMed ID: 15863961
[TBL] [Abstract][Full Text] [Related]
68. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
[TBL] [Abstract][Full Text] [Related]
69. Failure of somatostatin analogue to control Cushing's syndrome in two cases of ACTH-producing carcinoid tumours.
Cheung NW; Boyages SC
Clin Endocrinol (Oxf); 1992 Apr; 36(4):361-7. PubMed ID: 1424169
[TBL] [Abstract][Full Text] [Related]
70. Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate.
Hajarizadeh H; Ivancev K; Mueller CR; Fletcher WS; Woltering EA
Am J Surg; 1992 May; 163(5):479-83. PubMed ID: 1374222
[TBL] [Abstract][Full Text] [Related]
71. Use of somatostatin analog in management of carcinoid syndrome.
Vinik A; Moattari AR
Dig Dis Sci; 1989 Mar; 34(3 Suppl):14S-27S. PubMed ID: 2920654
[TBL] [Abstract][Full Text] [Related]
72. Tachykinins in the canine gastroesophageal junction.
Sandler AD; Maher JW; Weinstock JV; Schmidt CD; Schlegel JF; Jew JY; Williams TH
Am J Surg; 1991 Jan; 161(1):165-70. PubMed ID: 1702940
[TBL] [Abstract][Full Text] [Related]
73. Substance P, neurokinin A and neurokinin B in the ocular response to injury in the rabbit.
Beding-Barnekow B; Brodin E; Håkanson R
Br J Pharmacol; 1988 Sep; 95(1):259-67. PubMed ID: 2464386
[TBL] [Abstract][Full Text] [Related]
74. Occurrence and effects of multiple tachykinins; substance P, neurokinin A and neuropeptide K in human lower airways.
Martling CR; Theodorsson-Norheim E; Lundberg JM
Life Sci; 1987 Apr; 40(16):1633-43. PubMed ID: 2436021
[TBL] [Abstract][Full Text] [Related]
75. Carcinoid tumour cells in long-term culture: release of serotonin but not of tachykinins on stimulation with adrenoceptor agonists.
Ahlman H; Ahlund L; Nilsson O; Skolnik G; Theodorsson E; Dahlström A
Int J Cancer; 1988 Oct; 42(4):506-10. PubMed ID: 2902016
[TBL] [Abstract][Full Text] [Related]
76. Therapeutic principles in the management of metastasising carcinoid tumors: drugs for symptomatic treatment.
Gregor M
Digestion; 1994; 55 Suppl 3():60-3. PubMed ID: 7698539
[TBL] [Abstract][Full Text] [Related]
77. Terminal ileal carcinoid tumor without hepatic or extrahepatic metastasis causing carcinoid syndrome.
Datta J; Merchant NB
Am Surg; 2013 Apr; 79(4):439-41. PubMed ID: 23574858
[No Abstract] [Full Text] [Related]
78. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
79. Lung carcinoid with Cushing's syndrome: control of serum ACTH and cortisol levels using SMS 201-995 (sandostatin).
Hearn PR; Reynolds CL; Johansen K; Woodhouse NJ
Clin Endocrinol (Oxf); 1988 Feb; 28(2):181-5. PubMed ID: 2844445
[TBL] [Abstract][Full Text] [Related]
80. Octreotide exerts only acute, but no sustained, effects on MRI enhancement of liver metastases in carcinoid syndrome.
Zomerhuis MT; Hussain SM; Feelders RA; van der Lely AJ; de Herder WW
Neuroendocrinology; 2005; 82(1):41-8. PubMed ID: 16391492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
